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In Brief
Tumor-directed T cell responses play a
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development. Knocke et al. investigated
CD4 and CD8 T cell responses in mice
bearing liver tumors with tailored tumor
immunogenicity, and they characterized
the role of both cell types for efficient
tumor suppression with different types of
pre-defined tumor-specific antigens.
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CD4 and CD8 T cells play a pivotal role in controlling
tumor growth. However, the interplay of both cell
types and their role in tumor suppression still remain
elusive. In this study, we investigated the regulation
of CD4 and CD8 T cell responses to different classes
of tumor-specific antigens in liver cancer mouse
models. Tumors were induced in p19Arf-deficient
mice by hydrodynamic injection of transposon plas-
mids encoding NrasG12V and pre-defined tumor
antigens. This allowed for assessing the regulation
of tumor-specific CD4 and CD8 T cell responses.
We showed that MHC class I tumor immunogenicity
was essential to trigger tumor-directed CD4 T cells.
Tumor-specific CD8 T cell responses arose indepen-
dently of CD4 T cells, but they required Th1-polarized
CD4 T cells for efficient tumor suppression. Our
results further indicate that the immune system
is incapable of eliciting sufficient numbers of T cells
directed against antigens derived from immunoe-
dited tumors, which consequently leads to a lack
of T-cell-mediated tumor suppression in untreated
hosts.
INTRODUCTION
Inherent immune-mediated tumor-suppressive mechanisms
in immunocompetent hosts are restricted to distinct stages of
tumor development. Upon aberrant activation of oncogenes
such as ras, normal cells undergo cellular senescence (Lowe
et al., 2004), a tumor-suppressive mechanism, and enter a pre-
malignant state. Senescence surveillance targets pre-malignant
cells displaying a senescence-induced secretory phenotype
(SASP), and it drives an immune response dependent on CD4
T cells andmacrophages that finally leads to the clearance of se-
nescent cells (Kuilman et al., 2008; Kang et al., 2011). If the im-
mune system fails a timely clearance, pre-malignant cells may
be able to acquire additional genetic alterations, such as the
loss of tumor suppressor genes, bypass cellular senescence,
and proceed toward the malignant state. The immune system
is capable of clearing malignant cells by innate immune re-2234 Cell Reports 17, 2234–2246, November 22, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://sponses (O’Sullivan et al., 2012). Additionally, adaptive immune
responses have been shown to efficiently suppress tumor
growth (Shankaran et al., 2001). The ability to suppress cancer
by innate and adaptive immunity has been collectively termed
cancer immunosurveillance.
During early malignant states of tumor development, cancer
immunosurveillance is able to clear cancer or keep it in an occult
state (Koebel et al., 2007). In advanced stages of cancer, the
presence of intratumoral T cells can slow down tumor progres-
sion and inhibit dissemination, thus providing a significant sur-
vival benefit to patients (Galon et al., 2006). The hypothesis of
cancer immunosurveillance has been further refined to the tenet
of cancer immunoediting (Dunn et al., 2004; Mittal et al., 2014).
Due to this editing process, tumor-directed immune responses
shape tumors toward low immunogenicity. In line with this hy-
pothesis, T cell pressure on tumors has been shown to lead to
a loss of expression of a highly immunogenic passenger muta-
tion (Matsushita et al., 2012). It also has been demonstrated
that model antigens can underlie immunoediting by leading to
a deficiency of H2-Kb, which in turn prevents antigen presenta-
tion on tumor cells (DuPage et al., 2012). This implies that tumors
do not necessarily trigger T cell responses, and it pinpoints the
limitation of T cell-mediated surveillance of cancer.
Recent advances in cancer treatment are based on immune
checkpoint blockade that exploits the fundamental ability of the
immune system to generate adaptive tumor immunity by inhibit-
ing negative regulation pathways of T cells, such as CTLA-4 and
PD-1 (Maker et al., 2005; van Rooij et al., 2013; Topalian et al.,
2012). Several studies show that immunoedited cancer cells
frequently express putatively immunogenic epitopes but are still
able to progress rapidly without induction of detectable T cell re-
sponses in untreated hosts (Castle et al., 2012; Gubin et al., 2014;
Woller et al., 2015). However, there is strong evidence that
mutated CD8 T cell epitopes play a major role in responses of
autologous T cells to cancer (Lennerz et al., 2005; Castle et al.,
2012; Gubin et al., 2014; Kreiter et al., 2015). Additionally, it has
been reported that tumor-specific CD4 responses are frequently
observed inmelanomapatients (Linnemann et al., 2015) and they
also appear to be important for the efficacy of cancer immuno-
therapies (Ossendorp et al., 1998; Friedman et al., 2012; Tran
et al., 2014; Kreiter et al., 2015). However, the role of CD4 T cell
responses against tumor-specific antigens (TSAs) in the regula-
tion of T cell-mediated tumor clearance in cancer surveillance
and therapeutic approaches is still under debate.uthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
In this study, we investigated the interplay of CD4 and CD8
T cell responses in a transposon-based murine model of liver
cancer. Transposon vectors encoded oncogenic ras for tumor
induction and pre-defined TSAs comprising potent MHC class
I- and II-restricted epitopes to investigate T cell immunity during
tumor growth. We showed that tumor suppression and long-
term survival in this model were dependent on the interplay of
CD4 and CD8 T cells. Varying these TSAs allowed for studying
different aspects of the CD4 and CD8 compartment and their
role in tumor clearance. Furthermore, epitopes derived from im-
munoedited tumors were used to assess their features and ef-
fects on tumor immunity during tumor progression. The mouse
model established in the present study provides an excellent
tool for an in-depth study of all aspects of the molecular regula-
tion for tumor-directed T cell responses in a genetically defined
background.
RESULTS
Oncogenic Ras Rapidly Induces Cytotoxic T Cell
Responses
Oncogenic ras induces cellular transformation and is a main
driver of proliferation in many types of cancer (Chang et al.,
1982). Since ras plays a pivotal role in many aspects of cellular
malignancies, we hypothesized that it also may have an impact
on T cell immunity against cancer. To investigate the role of ras
in the induction of T cell responses, we generated a transposon
plasmid encoding ovalbumin (OVA) linked by an internal ribo-
somal entry site (IRES) motif to KrasG12V (OIR). As control, we
used the same plasmid backbone coding for OVA alone.
Upon hydrodynamic injection of the OIR transposon together
with a sleeping beauty transposase for stable integration in
hepatocytes, we detected OVA-specific responses in C57BL/6
mice on day 7. No response to OVA was detectable at this
time point if the expression of ras was absent (Figure 1A).
Furthermore, mutant forms of Nras, Kras, and Hras were able
to elicit OVA-specific responses when co-expressed with the
OVA expression vector (Figure 1B). In contrast, the specific
response was absent when either wild-type ras or the effector
loop mutant KrasG12V + D38A (Warne et al., 1993) was used.
These responses induced in this manner exhibited cytotoxic ac-
tivity, as shown by an in vivo cytotoxicity assay (Figure 1C).
To validate these results in an MHC-disparate mouse model
and with a different model antigen, we generated a transposon
vector coding for DNA-binding protein (dbp) derived from
adenovirus serotype 5. Dbp-specific CD8 T cell epitopes have
been characterized for H2-b and H2-d mice (McKelvey et al.,
2004). Expression of dbp in C57BL/6 (H2-b) revealed similar re-
sults as the use of OVA (Figure 1D). The same experiment was
performed in BALB/c mice (H2-d). Here, low dbp-specific
T cell responses were detectable in the KrasG12V +D38A group.
However, co-expression of ras induced significantly higher mag-
nitudes of T cell responses to dbp (Figure 1E).
Tumor-Specific T Cell Responses in the Malignant State
Suppress Tumor Development
To establish a versatile molecular tool for the investigation of tu-
mor-specific T cell responses, we cloned a transposon-basedTSA-NrasG12V expression vector. Short DNA fragments encod-
ing single T cell epitopes were inserted and concatenated into
this vector to allow for tailored tumor immunogenicity of MHC
class I- and II-restricted TSAs (from now on the individual T cell
antigen fragment is referred to as epitope tag). The epitope
tags were flanked by a 2A sequence followed by a coding
sequence for murine NrasG12V, which results in equal levels of
gene expression. First, we cloned all three MHC class I- and II-
restricted OVA antigens as epitope tags into the vector. Epitope
tags were flanked N- and C-terminally by five to 12 amino acids
of the corresponding full-length protein. This ensured that all
MHCclass I epitopes had to be processedbyproteasomal cleav-
age and enter the antigen-processing pathway similar to full-
length proteins. We compared the full-length OVA protein and
epitope tags in vivo by quantification of resulting T cell responses
upon hydrodynamic injection to verify similar antigen processing.
We also investigated Spnb2-R913L, a neoepitope that was
formerly described as an endogenous TSA of nascent/unedited
tumors. However, full-length Spnb2 consists of about 6.5 kb
and exceeds the capacity of transposon vectors. Therefore,
we restricted the size of Spnb2-R913L for antigen-processing
analysis to a 1.6-kb fragment, which is comparable to the size
of OVA, and we cloned this fragment into a transposon vector af-
ter inserting the mutation (Figure 2A). Upon in vivo application of
these vectors, we quantified T cell responses by enzyme linked
immunosorbent spot (ELISpot) assay analysis that derived
from epitope tags and proteins specific for OVA and Spnb2-
R913L (Figure 2A, right panel). These results demonstrate cor-
rect antigen processing of the CD8 epitope tags, and, moreover,
they show that the magnitude of corresponding T cell responses
is not significantly different between the two formats.
Next, we inserted an epitope tag encoding mutant spectrin-b2
into the NrasG12V vector containing all three OVA tags (O[MII]-
NrasG12V), resulting in SO(MII)-NrasG12V. Both MHC class I
antigens (Spnb2-R913L and OVA) induced potent CD8 T cell
responses when the vector was applied to p19Arf/ mice (dot-
plots in Figure 2B). Expression of ras in these mice induced hep-
atobiliary tumors upon hydrodynamic injection, in accordance
with results from previous studies (Carlson et al., 2005; Kang
et al., 2011). In contrast to NrasG12V, SO(MII)-NrasG12V
potently suppressed tumor development (illustrated by macro-
scopic liver inspection, Figure 2B). The SO(MII)-NrasG12V group
showed significantly lower liver weight as a surrogate of tumor
burden, and H&E sections of the liver revealed abundant lym-
phocytic tumor infiltration compared to the control (Figure 2B).
We assessed the induction of T cell responses and tumor pro-
gression in wild-typemice and p19Arf/mice that are incapable
of triggering senescence surveillance upon oncogenic stress
(the dotplots are shown in the same sequence as the indicated
applied constructs, Figure 2C). Compared to wild-type mice,
the induction of T cell responses in p19Arf/ mice was signifi-
cantly higher. In line with a previous study (Kang et al., 2011),
senescence induction by ras completely suppressed cancer
development in wild-type mice. Hence, no difference was
observable in liver weight between the NrasG12V and the
SO(MII)-NrasG12V group in wild-type mice. Furthermore, tumor
suppression in p19Arf/ mice was dependent on cytotoxic
T cell responses, which were rescued by the application ofCell Reports 17, 2234–2246, November 22, 2016 2235
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Figure 1. Oncogenic Forms of Ras Rapidly Induce T Cell Responses to Model Antigens in H2-b and H2-d Mice
(A) The depicted plasmids were delivered by hydrodynamic injection to C57BL/6 mice. On day 7 post-injection, splenocytes were stimulated with SIINFEKL and
analyzed by IFNg ELISpot analysis. SIYRYYGL peptides served as the control. Results show the absolute number of spot-forming units (SFUs) per 23 105 cells.
Mean ± SD; 6 mice/group; Student’s t test; *p < 0.05.
(B) A similar setup was used to investigate T cell responses induced by different forms of ras, as indicated in the figure (WT, wild-type; rasG12V, oncogenic forms
of ras; rasG12V + D38A, kinase-deficient [inactive] form). Mean ± SD; 3-8 mice/group; Student’s t test; *p < 0,05; **p < 0.01; ns > 0.05.
(C) An in vivo cytotoxicity assay was performed in mice upon hydrodynamic injection of Kras(G12V + D38A) + OVA and KrasG12V + OVA. The histograms display
representative results for OVA-specific cytotoxicity. Mean ± SD; 5 mice/group; Student’s t test; **p < 0.01.
(D) In H2-b mice (C57BL/6), an ELISpot was performed using the model antigen dbp with rasG12V and ras(G12V + D38A), respectively. H2-b-restricted GFP-
specific peptide was used as the control. Mean ± SD; 5 mice/group; Student’s t test; *p < 0.05.
(E) The same setup as in (D) was used with H2-d mice (BALB/c) and H2-d-restricted peptides. Mean ± SD; 5 mice/group; Student’s t test; **p < 0.01.CD8-depleting antibodies. Application of SO(MII)-NrasG12V to
p19Arf/ mice induced potent cytotoxic responses that were
detected by an in vivo cytotoxicity assay (Figure 2D).
To validate the regulation of T cell responses and to rule out that
the observations are due to the p19Arf/ phenotype, we as-
sessed the induction of T cells in an additional mouse model. To
this end,weusedwild-typeC57BL/6miceand transposonvectors
coding for myristoylated Akt1 (myrAkt1), and we cloned a domi-
nant-negative form of TRP53 (R246S). The latter construct also
included three small hairpin RNA (shRNA) motifs in the 30 UTR of
mutant TRP53 targeting the 30 UTR of endogenous TRP53 tran-
scripts to knock down wild-type TRP53. Compared to p19Arf/,
a similar growth kinetic was realized in wild-type mice when ras,
myrAkt1, and TRP53(R246S)-sh30TRP53 were used in the trans-2236 Cell Reports 17, 2234–2246, November 22, 2016poson setup (referred to as NrasG12V + Akt + Dp53 in Figure 2E).
This model showed similar levels of T cell responses and tumor
growth suppression as the p19Arf/ model, demonstrating
that our findings are not restricted to a particular genotype. How-
ever, since the model using p19Arf/ mice is genetically better
defined than co-expression of additional oncogenes and the
p19Arf/ model has been characterized extensively in several
studies (Kamijo et al., 1997; Carlson et al., 2005; Kang et al.,
2011), all further experiments were performed in p19Arf/ mice.
Next we wanted to rule out that the method of hydrodynamic
injection procedure plays a role in tumor suppression. To assess
T cell-mediated rejection of tumors in another independent
experimental system, we generated tumor cell lines that had
been established from tumors in mice by application of the
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(legend on next page)
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control (NrasG12V) andSO(MII)-NrasG12V vectors. The resulting
cell lines (HepN and HepSOMIIN) were applied subcutaneously
to C57BL/6 mice and tumor growth was monitored (Figure 2F).
The HepN tumor grew progressively and all mice succumbed to
a high tumorburdenwithin 3weeks,whereasHepSOMIIN tumors
were completely rejected within the first 2 weeks. HepSOMIIN
tumor growth was prolonged or rescued by CD8-depleting
antibodies (four of five mice showed progressive tumor growth)
and also by antibody-mediated CD4 depletion (three of five
mice had progressively growing tumors). On day 14, we investi-
gated peripheral blood for the occurrence of tumor-specific
CD8 T cells. Mice with engrafted HepSOMIIN cells displayed
high amounts of Spnb2-R913L- and OVA-specific cells. These
cells also could be detected in similar magnitudes in the CD4-
depleted group. Hence, in subcutaneous tumor models using
isogenic cells, the tumor immunogenicity and rejection was
comparable to tumor models using hydrodynamic injection.
Tumor-Specific T Cell Responses Mediate Long-Term
Survival
So far we demonstrated that T cells play a key role in tumor
growth suppression in this model. To characterize these re-
sponses in more detail, we investigated tumor lesions with
H&E andCD45 using immunohistochemistry (IHC), andwe found
a significant increase in immune cells in tumors of the SO(MII)-
NrasG12V group compared to NrasG12V alone (Figure 3A). In
contrast to the control group, SO(MII)-NrasG12V induced a
significant shift toward CD8 in the intratumoral CD90 T cell pop-
ulation. Accordingly, we detected high amounts of intratumoral
SO-specific T cells by pentamer staining (Figure 3B). Antigen-
specific stimulation of CD8 T cells led to the induction of IFNg
and TNF-a. The amount of double-positive T cells for Spnb2-
R913L was 26.15% (±2.77 SEM) and for OVA was 30.85%
(±4.24 SEM). The results indicate that there is no significant
difference in cytokine expression between a model antigen
and a mutated tumor antigen (Figure 3C).
To assess whether variable degrees of tumor progression
can be realized by different configurations of T cell epitope
tags in this model, we investigated corresponding tumor growth
for NrasG12V, S(MII)-RasG12V, O(MII)-Ras-G12V, and SO(MII)-Figure 2. Tailored Tumor Immunogenicity Potently Suppresses NrasG
(A) OVA-specific T cell epitopes for C57BL/6 mice and the Spnb2-R913L epitope
Transposons encoding full-length (FL) OVA and a 1.6-kb fragment of Spnb2-R913
and proteins upon hydrodynamic injection were compared by ELISpot analysis.
(B) An epitope tag coding for Spnb2-R913L was added to the O(MII)-NrasG12V t
both MHC class I TSAs in individual mice was confirmed by pentamer staining
suppression by T cell responses after the application of SO(MII)-NrasG12V or N
phocytic infiltration in H&E-stained sections. Mean ± SD; 5 mice/group; Student
(C) Tumor suppression and induction of T cell responses weremonitored in wild-ty
mice were sacrificed, liver weight was determined, and OVA- and Spnb2-R913
mediated depletion of CD8 T cells was performed to investigate the role of CD8
**p < 0.01; ***p < 0.001; ns > 0.05.
(D) An in vivo cytotoxicity assay was performed in p19Arf/mice to determine the
5 mice/group; Student’s t test; ***p < 0.001.
(E) A similar experimental setup as in (C) was performed to validate previous exper
and TRP53-R246S-sh30TRP53 expression vectors. Mean ± SD; 5 mice/group; S
(F) Upon the generation of tumor cell lines HepN and HepSOMIIN from p19Arf/
were established in syngeneic mice. Tumor growth is shown for individual mice
SO-specific responses were quantified on day 14 and are shown in the right pan
2238 Cell Reports 17, 2234–2246, November 22, 2016NrasG12V. As shown in Figure 3D, there was a gradual decrease
in liver tumor burden detectable as assessed by liver weight
measurements. The sequence of tumor burden was NrasG12V
>> S(MII)-NrasG12V > O(MII)-NrasG12V > SO(MII)-NrasG12V.
Consistently, an increase in T cell responses dependent on
CD8 T cell epitopes encoded by the transposon vectors
was observed. These results indicate that tumor immunogenicity
is linked to increasing numbers of immunogenic T cell epitope
tags.
Upon injection of NrasG12V and SO(MII)-NrasG12V vectors
into p19Arf/mice, wemonitored survival (Figure 3E). The injec-
tion of NrasG12V led to a rapid tumor progression and all
mice had to be sacrificed due to a high tumor burden before
day 40. In sharp contrast, the immunogenic SO(MII)-NrasG12V
construct mediated tumor suppression and a significant survival
benefit with 40% long-term survivors. We terminated the exper-
iment on day 220 and monitored the tumor immune responses
in those mice. All mice had low but detectable amounts of
Spnb2-R913L- and OVA-specific T cells (Figure 3F). Finally, we
compared the cytotoxicity of the tumor-specific response in
SO(MII)-NrasG12V-treated mice that developed tumors at day
130 with two mice of the same group with no visible tumors. In
contrast to the widespread tumor growth of non-immunogenic
tumors within the whole liver of the NrasG12V group, tumor
growth of SO(MII)-NrasG12V-treated mice at late time points
was limited to outgrown single-tumor nodules (Figure 3G).
Furthermore, cytotoxicity was much higher in tumor-bearing an-
imals, indicating that cytotoxic tumor responses correlate with
the tumor burden. Moreover, the balance between the tumor
growth rate and the counteracting cytotoxic T cell response ap-
peared here to be in favor of tumor progression, demonstrating
that tumor-directed T cell responses and tumor progression in
this model can co-exist at the same time.
Th1-Polarized Helper Cell Responses Are Required to
Clear Tumor Cells, Do Not Alter the Magnitude of CD8 T
Cell Responses, and Arise in Dependence onMHCClass
I Tumor Immunogenicity
To investigate the relationship between the regulation of CD4
and CD8 T cell responses, we performed a CD4 T cell depletion12V-Mediated Tumor Development in p19Arf/ Mice
were cloned as epitope tags into an NrasG12V expression vector as shown.
L were used as the controls. On day 24, the induction of T cell responses of tags
Mean ± SD; 5 mice/group; Student’s t test; ns > 0.05.
ransposon to obtain SO(MII)-NrasG12V. Induction of T cell responses against
following the application to p19Arf/ mice, as shown in the dotplots. Tumor
rasG12V alone was assessed by total liver weight and the detection of lym-
’s t test; **p < 0.01.
pe and p19Arf/mice upon application of the indicated constructs. On day 24,
L-specific T cell responses were quantified by pentamer staining. Antibody-
responses for tumor suppression. Mean ± SD; 5 mice/group; Student’s t test;
tumor cytotoxicity induced by the indicated constructs on day 24. Mean ± SD;
iments in wild-typemice with and without the additional application ofmyrAkt1
tudent’s t test; *p < 0.05; **p < 0.01; ***p < 0.001.
mice injected with corresponding transposon vectors, subcutaneous tumors
of each group. Depleting antibodies were applied twice weekly as indicated.
el. Mean ± SD; 5 mice/group; Student’s t test; ns > 0.05.
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Figure 3. Interactions between T Cell Responses and Tumor Development
(A) Analysis of tumor-residing lymphocytes by histology and immunohistochemistry. NrasG12V and SO(MII)-NrasG12V tumors were investigated for tumor-
residing leukocytes by histology and immunohistochemistry. The graph displays quantifications of mean fluorescence intensity (MFI) of CD45 within the tumor
area. Mean ± SD; 5 mice/group; Student’s t test; ***p < 0.001.
(B) Tumor-infiltrating T cells were analyzed by flow cytometry. The left graph depicts relative changes of CD8 T cells within the total T cell pool (based on CD90+
TILS). Pentamer-positive cells are shown in the right panel. Mean ± SD; 5 mice/group; Student’s t test; ***p < 0.001.
(C) IFNg and TNF-a secretion of stimulated tumor-specific T cells was quantified in an intracellular cytokine staining by flow cytometry. The graph shows the ratio
of IFNg and TNF-a double-positive CD8 T cells to total IFNg-secreting CD8 T cells. Mean ± SD; 5 mice/group; Student’s t test; ns > 0.05.
(D) The ability to mediate tumor suppression in dependence on tumor immunogenicity was investigated upon the application of depicted transposon constructs.
On day 24, liver weight was determined and T cell responses were quantified by IFNg ELISpot. Mean ± SD; 5 mice/group; Student’s t test; *p < 0,05; **p < 0.01;
ns > 0.05.
(E) Survival of p19Arf/ mice injected with NrasG12V and SO(MII)-NrasG12V was followed up for 220 days. Mean ± SD; 10 mice/group; Log-rank (Mantel-Cox)
test; ***p < 0.001.
(F) At the end of the survival experiment, T cell responses were quantified by pentamer staining. This figure shows pooled data from two independent experi-
ments. Mean ± SD.
(G) Cytotoxicity and liver tumor burden were inspected in mice with late-occurring tumors (day 130) and compared to mice with no macroscopic tumors of the
same group. Mean ± SD.
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experiment in mice that were injected with SO(MII)-NRasG12V,
and we followed up on tumor development and the induction
of CD8 T cell responses. As shown in Figure 4A, antibody-medi-
ated CD4 depletion rescued tumor progression. Surprisingly, the
development of CD8 responses was not affected in the CD4-
depleted group. To further validate these results, we generated
the construct SO-NrasG12V to deprive the developing tumor
of potent MHC class II-specific epitopes (Figure 4B). Application
of this MHC class II-negative construct led to similar results as
antibody-mediated depletion of CD4 T cells. Again, tumor sup-
pression was not detectable, and themagnitude of CD8 T cell re-
sponses between the SO-NrasG12V and the SO(MII)-NRasG12V
groups was found to be not significantly different. In the
latter group, we also detected CD4 T cell responses in an IFNg
ELISpot with a pool of both I-Ab-restricted OVA-specific pep-
tides. This assay revealed a specific induction of IFNg-releasing
CD4 T cells. Themagnitude was independent of whether epitope
tags or full-length OVA vectors were used (Figure 4C). This
response was restricted to CD4 T cells that expressed T-Bet, a
transcription factor specific for Th1 responses. Furthermore,
peptide-specific stimulation of CD4 T cells induced secretion
of TNF-a and IL-2 (data not shown).
We additionally cloned (MII)-NrasG12V to analyze the CD4
T cell response in the absence of MHC class I-restricted tumor
immunogenicity (Figure4D), andweobservedno tumor-suppres-
sive activity. Unexpectedly and in contrast to SO(MII)-NrasG12V,
no CD4-specific response could be detected upon application of
(MII)-NrasG12V to mice, as shown by an IFNg ELISpot analysis.
Further analysis of liver tumor sections by immunohistochemistry
showed that CD4 T cells are abundantly present in the tumor
margin of SO(MII)-positive tumors (Figure 4E). SO-NrasG12V
induced a low magnitude of CD4 T cells in the tumor margin,
but these CD4 cells were not sufficient to mediate tumor su-
ppression. However, the presence of CD4 T cells in tissue of
SO-NrasG12V tumors supports the hypothesis that MHC
class I T cell immunogenicity is involved in thegenerationof effec-
tiveCD4Tcell responses. In (MII)-positive tumors, almost noCD4
Tcellsweredetectable in the tumor tissueand therewasnoquan-
titativedifferencecompared to thecontrol group. Taken together,
the results demonstrate a mutual dependence of CD4 and CD8
T cell responses as a precondition for efficient tumor suppres-
sion. Figure 4F shows an in vivo cytotoxicity assay for CD4
T cells of SO(MII)-NRasG12V-treated mice. In contrast to the
SO-specific CD8 response, a very low but statistically significant
CD4 cytotoxicity was observable to OVA MHC class II-pulsed
CD19 target cells, which may be attributable to Th1-cytokine
secretion. However, the results also showed that CD8 T cells
mediate the main effect of tumor-specific cytotoxicity.
The Immune System Is Incapable of Eliciting Efficient
T Cell Responses against MHC Class I- and II-Restricted
TSAs from Immunoedited Tumors by Cancer
Surveillance in Untreated Mice
So far we used potent rejection and model antigens to investi-
gate the regulation of cancer-induced T cell immunity. However,
these antigens do not resemble the clinical situation of immunoe-
dited tumors. To assess epitopes from edited tumors in an
antigen-specific manner, we cloned two MHC class I epitope2240 Cell Reports 17, 2234–2246, November 22, 2016tags coding for Ndufs1-V491A and Lama4-G1254V, which
have been described to be responsive for immune checkpoint
blockade in the progressively growing parental cell lines, into
the transposon vector (Gubin et al., 2014; Woller et al., 2015).
These epitope tags were concatenated to OVA MHC class II
tags to provide sufficient CD4 help for tumor suppression. The
resulting construct NL(MII)-NrasG12V was applied to p19Arf/
mice. NrasG12V and SO(MII)-NrasG12V vectors served as con-
trols. As shown in Figure 5A, a high tumor burden indicated that
epitopes from immunoedited tumors do notmediate effective tu-
mor suppression. Hence, the results are in accordance with pre-
vious studies (Gubin et al., 2014;Woller et al., 2015). Flow cytom-
etry analysis of intracellular IFNg in CD8 T cells upon antigen
stimulation revealed low levels of T cell responses to Ndufs1-
V491A and Lama4-G1254V. The amounts of T cells induced by
antigens derived from immunoedited tumors were significantly
lower than responses to rejection antigens, such as Spnb2-
R913L and OVA. Furthermore, the quantification of CD4 T cell
responses revealed that there was no difference between the
NL(MII)-NrasG12V and the SO(MII)-NrasG12V groups, demon-
strating that a low MHC class I immunogenicity is sufficient to
trigger CD4 responses (Figure 5A).
In Figure 5B we assessed whether Ndufs1-V491A-specific
T cells can be expanded by dendritic cell (DC) vaccination. Toll-
like receptor (TLR)-activated DCs induced high levels of anti-
gen-specific T cells. These findings show that the Ndufs1-T cell
precursor number is sufficient to induce high amounts of T cells
upon vaccination, but the immune system in untreated tumor-
bearing hosts is not capable of triggering tumor-directed T cell re-
sponses. Finally, we investigated the regulation of CD4 T cell re-
sponses to model antigens and neoantigens in dependence on
ras and MHC class I immunogenicity in C57BL/6 and p19Arf/
mice (Figure 5C). For this purpose, we generated the transposon
expression vectors Spnb2-R913L-Kif18b-K739N-OVA265–280-
OVA323–339 (SKO), Kif18b-K739N-OVA265–280-OVA323–339-2A-
NrasG12V (KON), and Spnb2-R913L-Kif18b-K739N-OVA265–280-
OVA323–339-2A-NrasG12V (SKON). Kif18b-K739N is a CD4 T cell
epitope that has been identified as a potent MHC class II antigen
that drives tumor regression upon application of an RNA vaccine
(Kreiter et al., 2015). Corresponding vectors were delivered to
wild-type and p19Arf/mice, respectively. On day 7 the immune
response to each epitopewasdetermined byELISpot. Apart from
thehighermagnitudeofT cell responses inp19Arf/mice, the re-
sults in both mouse strains were similar. Application of SKO and
KON did not trigger any T cell response. Only when a potent
MHC class I epitope and ras were co-expressed by the SKON
vector were CD4 T cell responses to MHC class II epitopes of
OVA and CD8 responses to Spnb2-R913L detectable. These re-
sults show that the immune system is unable to induce CD4
T cell immunity to Kif18b-K739N when this epitope is expressed
by a tumor, and they also confirm that induction of CD4 T cell im-
munity to OVA265–280 and OVA323–339 is dependent on ras and
MHC I immunogenicity.
DISCUSSION
During tumor development, pre-malignant and malignant
phases can be distinguished. In a previous study, Kang et al.
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Figure 4. Interplay of Tumor-Specific CD4 and CD8 T Cells Mediates Tumor Suppression
(A) The role of CD4 T cells in this model was investigated by the application of CD4-depleting antibodies upon the injection of SO(MII)-NrasG12V into p19Arf/
mice. Liver weight was determined and CD8 T cell responses were quantified by pentamer staining. The NrasG12V group and the isotype-treated SO(MII)-
NrasG12V group served as the controls. Mean ± SD; 5 mice/group; Student’s t test; **p < 0.01; ns > 0.05.
(B) The construct SO-NrasG12V was generated and injected into p19Arf/ mice, and tumor development was investigated and compared to control groups.
Liver weights and results from pentamer staining are shown in the corresponding graphs. Mean ± SD; 5 mice/group; Student’s t test; ***p < 0.001; ns > 0.05.
(C) MHC class II responses specific for both OVA-derived I-Ab epitopes were measured by ELISpot in the NrasG12V and SO(MII)-NrasG12V groups. Full-length
OVA (FL-OVA-NrasG12V) served as the positive control. Additionally, peptide-stimulated IFNg-secreting CD4 T cells were analyzed for the expression of T-Bet.
Mean ± SD; 5 mice/group; Student’s t test; ***p < 0.001; ns > 0.05.
(D) The transposon (MII)-NrasG12V was cloned and injected into p19Arf/ mice. Tumor development was compared to control groups. Quantification of liver
weight and CD4-specific tumor immune responses is shown in the graph. Mean ± SD; 5 mice/group; Student’s t test; ***p < 0.001; ns > 0.05.
(legend continued on next page)
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(2011) showed that oncogenic stress by ras in hepatocytes leads
to effective elimination of these pre-malignant cells by CD4
T cells and macrophages, but not CD8 T cells. This process
has been termed senescence surveillance. In our study, we
found that oncogenic forms of ras, delivered to immunocompe-
tent C57BL/6 mice by hydrodynamic injection of transposon
plasmids, rapidly induce CD8 T cell responses to potent anti-
gens. This observation was unexpected since ras-positive hepa-
tocytes should be rapidly cleared by senescence surveillance.
Hence, ras-induced T cell responses cannot simply be explained
by a higher antigenic load associated with proliferating tumor
cells. Since CD8 T cell responses do not play a role in the pre-
malignant state, it suggests that ras induces or accelerates the
generation of T cells during the malignant state. Accordingly,
we observed a significantly higher number of tumor-specific
T cells when ras was injected into p19Arf/mice. The p19Arf/
model includes a defect in the induction of cellular senescence
by oncogenic stress due to blunting the p19Arf-dependent inhi-
bition of MDM2-mediated p53 degradation (Kamijo et al., 1997;
Pomerantz et al., 1998). Thus, stable expression of ras in p19Arf-
knockout mice leads to malignant transformation without trig-
gering cellular senescence, and it elicits T cell responses to
TSAs that suppressed tumor growth in our model. We showed
that these effects were not due to the p19Arf knockout itself,
since the same results were obtained in C57BL/6 wild-type
mice when amodified transposon setup was used. Furthermore,
we ruled out that the observations are influenced by the method
of hydrodynamic injection by comparing the findings with a sub-
cutaneously engrafted model using isogenic cell lines.
The design of tumor immunogenicity in our study was based
on transposon vectors coding for the driver oncogene NrasG12V
strictly linked to TSAs by a 2Amotif to avoid the effects of immu-
noediting to the greatest possible extent (Schreiber et al., 2011).
When hepatocytes were transformed by ras alone, cells conse-
quently lacked non-self-antigens and rapid tumor progression
occurred. This result supports the general notion that mutated
neoantigens are required for T cell-mediated tumor rejection
(Lennerz et al., 2005; van Rooij et al., 2013; Gubin et al., 2014).
All tumor-specific antigens were expressed by epitope tags.
These epitope tags were similarly processed as their larger
conterparts or even full-length proteins and elicited similar
T cell responses. We used potent H2-Kb- and I-Ab-restricted
ovalbumin epitopes and additionally introduced the only known
H2-Db-restricted TSA from unedited tumors, namely Spnb2-
R913L, which was identified in sarcoma models (Matsushita
et al., 2012), to assess the immune regulation of cancer-induced
T cells. This allowed for comparison between a model antigen
and a mutated TSA in individual mice. We found no differences
in the cytokine expression pattern, indicating that the pheno-
types of T cells specific for model antigens and neoepitopes
are similar. However, tumor immunogenicity of the model anti-(E) CD4 IHC from the indicated groups was performed to validate systemic CD4
within livers. Clusters of CD4 cells are marked by arrows.
(F) Cytotoxic activity of tumor-inducedCD4 T cells was investigated in an in vivo cy
target cells. These cells were adoptively transferred to p19Arf/ mice that rece
cytotoxicity, CFSE+ target cells were gated on CD19 by flow cytometry. Analysis
5 mice/group; Student’s t test; ***p < 0.001; *p < 0.05.
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induced T cells.
Furthermore, we addressed the regulation of CD4 and CD8
T cell responses in tumor-bearingmice by depletion experiments
and by dissecting MHC class I and II TSAs encoded by the vec-
tors. Tumor suppression effectively occurred when both MHC
class I and II TSAs were expressed by the tumor. When only
MHC class I TSAs were expressed by tumor cells, themagnitude
of CD8 T cell responses was not different from tumors that addi-
tionally expressed class II epitopes. The same results were ob-
tained when CD4 T cells were depleted, demonstrating that the
expansion of cancer-specific CD8 T cells is not dependent on
CD4 T cells. However, when tumor cells lackedMHC class II epi-
topes, tumor suppression did not occur, although high numbers
of CD8 T cells were detectable. Interestingly, when solely MHC
class II epitopes were expressed by cancer cells, no CD4
response was triggered. These results demonstrate the mutual
dependence of CD4 andCD8T cell responses that have to coop-
erate to eliminate tumor cells. Penaloza-MacMaster et al. (2015)
revealed that vaccine-elicited CD4 T cells induce immunopa-
thology following chronic lymphocytic choriomeningitis virus
(LCMV) infection. Hence, the presence of potent CD4 T cell re-
sponses without CD8 T cells is capable of mediating a cytokine
storm and catastrophic inflammation in infection models. Like-
wise, the missing generation of a tumor-directed CD4 T cell
response in the absence of MHC class I tumor immunogenicity
may protect the host from immunopathology. Moreover, the
investigation of T cell responses upondelivery of transposon vec-
tors encoding different combinations of TSAs and ras confirmed
that thegenerationofCD4 responses requiresMHCclass I immu-
nogenicity and oncogenic ras in wild-type and p19Arf/ mice.
A T helper-1 polarization of autologous tumor-specific CD4
T cells in our model appears to be a general feature of the
immune system, since this also has been described in human
cancers (Tran et al., 2014). An in vivo cytotoxicity assay of CD4
T cells demonstrated that these cells in the context of cancer
only exhibit marginal cytotoxicity. This cytotoxicity may be
explained by secretion of Th1 cytokines that could be crucial
to allow for CD8-mediated clearance of tumor cells. The study
of Kreiter et al. (2015) also demonstrated that vaccination using
CD4 T cell epitopes strongly induces tumor regression, which
apparently contradicts our results. However, eliciting CD4 re-
sponses by vaccination could have an influence on the CD4
T cell polarization, which subsequently alters cellular functions.
Long-term follow-up of mice that survived injections of
SO(MII)-NrasG12V showed that T cell immunity is maintained
over time at low levels. Some mice developed tumors at late
time points (day 130), demonstrating that tumors in this model
can become temporarily occult. Tumor escape was evident by
outgrowing single-tumor nodules that induced potent cytotox-
icity, suggesting a coexistence of tumors and tumor-specific-specific immune responses and to investigate the distribution of CD4 T cells
totoxicity assay. Therefore, bothOVAMHC class II epitopes were used to pulse
ived injections of NrasG12V and SO(MII)-NrasG12V, respectively. To analyze
of SO-specific cytotoxicity of CD8 T cells served as the control. Mean ± SD;
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Figure 5. Cancer Immunosurveillance Is Not Capable of Eliciting Sufficient T Cell Responses for Tumor Suppression against MHC Class
I-Restricted Epitopes Derived from Immunoedited Tumors
(A) To investigate tumor-directed T cell responses to epitopes derived from immunoedited tumors, we generated the construct NL(MII)-NrasG12V that contains
epitope tags of the epitopes Ndufs1-V491A and Lama4-G1254V. This construct was injected into p19Arf/ mice, and tumor development was compared to
NrasG12V and the SO(MII)-NrasG12V groups. Liver weights and results from quantified CD8 and CD4 T cell responses by intracellular IFNg staining are shown in
corresponding graphs. Mean ± SD; 5-8 mice/group; Student’s t test; ***p < 0.001; **p < 0.01; *p < 0.05; ns > 0.05.
(B) A DC vaccination was performed to assess the induction of T cell responses to Ndufs1-V491A. The dotplot displays a representative result. Mean ± SD;
5 mice/group; Student’s t test; ***p < 0.001.
(C) The figure shows results of CD4 responses to MHC class II OVA epitopes and the neoantigen Kif18b-K739N in dependence of Spnb2-R913L and NrasG12V.
Indicated constructs were injected into WT and p19Arf/ mice, respectively. On day 7 the immune responses for each antigen were measured by ELISpot.
Mean ± SD; 5 mice/group; Student’s t test; ***p < 0.001; **p < 0.01; ns > 0.05.T cells with a correlation between tumor burden and the magni-
tude of T cell responses.
Epitopes such as OVA and Spnb2-R913L are highly immuno-
genic and are, therefore, useful to study the regulation of T cell
responses against cancer. However, tumors that have under-
gone immunoediting do not induce potent T cell epitopes and,
thus, do not closely mimic the clinical situation. Therefore, we
further investigated the epitopes Ndufs1-V491A and Lama4-G1254V in our tumor model that were identified from immunoe-
dited tumors and have been shown to trigger T cell responses
upon immune checkpoint blockade. These epitopes do not
induce T cell responses or tumor regression in untreated hosts
using the parental cell line (Gubin et al., 2014; Woller et al.,
2015). An MHC class II epitope Kif18b-K739N identified from
melanoma cells did not elicit any detectable CD4 T cell response
in ourmodel, showing that this epitope also escapes surveillanceCell Reports 17, 2234–2246, November 22, 2016 2243
by the immune system in untreated mice. In our tumor model,
CD8 neoepitopes elicited low magnitudes of CD8 T cells, and,
in contrast to (MII)-NrasG12V, they rescued the generation of
a potent CD4 T cell response. Moreover, the resulting T cell
responses of both epitopes were significantly lower than re-
sponses to OVA and Spnb2-R913L in an isogenic setup.
Despite the fact that these epitopes poorly stimulate T cell re-
sponses in tumors, they can be used to trigger potent tumor re-
sponses and even tumor regression upon therapeutic applica-
tions. Kif18b-K739N induces potent tumor regression upon
RNA vaccination (Kreiter et al., 2015), Lama4-G1254V is highly
responsive upon immune checkpoint blockade (Gubin et al.,
2014), and Ndufs1-V491A can be used to induce high numbers
of T cells by DC vaccination, as shown in our study. The obser-
vation that all these epitopes from immunoedited tumors are
able to induce strong and effective T cell responses in different
therapeutic settings indicates that they are not weakly immuno-
genic in general. In terms of binding affinity predictions by com-
puter-based algorithms, both epitopes Ndufs1 (affinity 35 nM,
based on NetMHCI 4.0) and Lama4 (affinity 3 nM) have similarly
strong binding affinities to theMHC class I compared to rejection
antigens, such as Spnb2 (affinity 8 nM) and OVA (affinity 19 nM).
The efficient expansion of naive precursor T cells upon immuno-
therapeutic interventions (Ndufs1) and tumor remissions upon
checkpoint blockade (Lama4) suggest that weak MHC:TCR
(T cell receptor) interactions are not the crucial factor for insuffi-
ciently induced T cell priming. The replacement of Spnb2 and
OVA in the SO(MII)-NrasG12V vector to Ndufs1 and Lama4
(NL(MII)-NrasG12V) provides equal conditions for putative tumor
rejection. However, NL tumors grow progressively and do not
elicit relevant amounts of T cells, even when potent CD4 help
is present. This approach in a genetically defined mouse model
circumvents immunosuppressive mechanisms to ward off or
exhaust T cell responses that could have developed in estab-
lished cell lines of subcutaneous tumor models by cancer
immunoediting. Thus, low immunogenicity is not necessarily an
inherent feature of T cell epitopes from immunoedited tumors.
They are rather unresponsive to cancer immunosurveillance
in untreated hosts. The results also show that T cell epitopes
responsive to checkpoint blockade do not necessarily underlie
immunoediting during tumor development.
In summary, our study demonstrates that the ras oncogene
rapidly establishes T cell immunity, and it elucidates how tumor
immunogenicity affects the interrelated CD4 and CD8 T cell re-
sponses to different classes of TSAs.EXPERIMENTAL PROCEDURES
Mice
The 6- to 8-week-old C57BL/6 and BALB/c mice were obtained from Hann-
over Medical School animal facility. The p19(Arf)-null mice (Cdkn2atm1Cjs) on
a C57BL/6 background were kindly provided by Dr. L. Zender and bred in
the animal facility of Hannover Medical School. All in vivo experiments were
conducted according to the German guidelines for animal care and use of lab-
oratory animals (TierSchG) with the approval of the local legal authorities.
Generation of Transposon Plasmids
A modified form of the transposon plasmid pT3/EF1a plasmid (Xin Chen,
UCSF, Addgene plasmid 31789) was used for this study. Murine HrasG12V2244 Cell Reports 17, 2234–2246, November 22, 2016and KrasG12V were generated from wild-type expression vectors pORF-
mKRAS2 and pORF-mHRAS (both from InvivoGen) by PCRmutagenesis using
standard methods and cloned into pT3/EF1a. The murine sequence of Nras
(Genbank: BC058755.1) was cloned by the assembly of oligonucleotides
and inserted into pT3/EF1a. The basic construct for epitope tags linked by a
2A sequence to NrasG12V was generated by PCR. In brief, a start codon
was introduced into the multiple cloning site (MCS) followed by NheI/SpeI re-
striction sites allowing for concatenating epitope tags. This locus is followed by
a PCR-generated 2A-NrasG12V sequence. Each T cell epitope tag was PCR-
generated and consists of the DNA fragment coding for the minimal peptide
sequence flanked by five to 12 amino acid residues on the N and C termini
of the corresponding protein. The termini are flanked byNheI and SpeI restric-
tion sites for cloning into the transposon vector. Epitope tags were concate-
nated sequentially. A 1.6-kb Spnb2 fragment was amplified from CMT64
cDNA using the primers 50-AAGCTAGCGCCCACATGGAGTTCTGCTATC
AAG-30 and 50-AAACTAGTCCCCTGGGTGACCATCTCGCCCATG-30. A sub-
sequent PCR mutagenesis was applied to obtain the R913L mutant form.
Trp53 (GenBank: NM_011640.3) was PCR-amplified from cDNA derived
from the cell line CMT64 using the primers mp53-fw 50-TTTAAGCTTATGA
CTGCCATGGAGGAGTCAC-30 and mp53-rev 50-TTTGCGGCCGCTCAGTC
TGAGTCAGGCCCCAC-30, digested and cloned into pBlueScript. This
construct was used as the template for PCRmutagenesis to obtain the mutant
form of TRP53-R246S, which was cloned into pT3/EF1a-sh30TRP53 to obtain
pT3/EF1a-TRP53-R246S-sh30TRP53. pT3/EF1a-sh30TRP53 and pT3/EF1a-
myrAkt1 have been described previously (Brinkhoff et al., 2014). All constructs
used in this study were validated by Sanger sequencing.
Analyses of T Cell Responses by Flow Cytometry
The following antibodies were obtained from BioLegend: CD8-FITC and
unlabeled (53-6.7), CD4-FITC and unlabeled (GK1.5), CD90.2-PerCP (30-
H12), IFNg-APC (XMG1.2), TNF-a-PE (MP6-XT22), IL-2-PE (JES6-5H4), and
CD19-APC (6D5); and from eBioscience: T-Bet-PE (eBio4B10). Pentamer-
specific CD8 T cells from blood and tumors were stained by ovalbumin-spe-
cific (SIINFEKL, H2-Kb) and spectrin-b2 R913L-specific (VAVVNQIAL, H2-Db)
pentamers (both from ProImmune), according to the manufacturer’s instruc-
tions. To obtain tumor infiltrating lymphocytes (TILs), tumor tissue was minced
and further digested for 30 min at 37C by adding RPMI containing 200 mg/ml
each of collagenaseIA, collagenaseIV, and hyaluronidase and 50 mg/ml DNase
(all from Sigma-Aldrich). Suspension was then passed through a 40-mm cell
strainer and washed three times. Lymphocytes were obtained after ficoll
gradient centrifugation, which was performed according to standard proto-
cols. All single-cell suspensions from blood, spleen, and tumors were stained
with antibodies for 20 min at 4C.
Intracellular staining of tumor-specific CD4 and CD8 T cells to detect
T-Bet, IFNg, TNF-a, and IL-2 was performed according to the manufacturer’s
recommendations (Becton Dickinson). The cytotoxicity of T cell responses
was determined in an antigen-specific manner by an in vivo cytotoxicity assay
as described (Woller et al., 2015). Generation of Ndufs1-V491A-specific T cells
by DC vaccination was performed as described (Woller et al., 2011).
ELISpot Analysis
The numbers of IFNg-secreting splenocytes activated by antigen-specific
peptides were determined by ELISpot assays as described before (Woller
et al., 2015). The numbers in all graphs refer to absolute spot numbers of
2 3 105 cells per well.
Histology and Immunohistochemistry
Liver tissue was fixed with paraformaldehyde. Paraffin-fixed 2-mm sections
were stained with H&E according to standard protocols. CD45 (Invitrogen,
ab25386) and CD4 (eBioscience, 4SM95) immunohistochemistry was
performed according to standard methods. Secondary Alexa Fluor 488
goat anti-rat IgG (H+L) antibody from Invitrogen was used for all IHC
stainings.
Statistics
The data were analyzed by an unpaired, two-tailed t test when two distinct
groups were compared. A log-rank test was applied to survival curves to
determine statistical significance. The p values of 0.05 or less were considered
statistically significant. GraphPad Prism 5 software was used for analysis.
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